RxDoctor Payments Data

Robert Charlson, MD

Neurology · New York, NYNPI 1265636997

Payments from drug & device makers

$57,285in general payments, 2019–2025

Across 87 payments — averaging $658.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$56K
  • Novartis$409
  • EMD Serono, Inc.$394
  • AstraZeneca$282
  • Bristol Myers Squibb$151
  • Genentech USA, Inc.$138
  • plus $311 from 3 others

What the payments were for

  • Food & beverage$1,875100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen15$55,600
Novartis16$409
EMD Serono, Inc.17$394
AstraZeneca13$282
Bristol Myers Squibb6$151
Genentech USA, Inc.6$138
TG Therapeutics, Inc.6$138
Cycle Pharmaceuticals Inc4$88
Amgen4$86

How this compares

$57,285 in reported general payments places this provider in the 80th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$52,825
Medicare patients
191
Services billed
480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab133$1,193,276
TecfideraDimethyl Fumarate56$521,510
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5011$291,758
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5029$287,106
OctagamImmun Globg(Igg)/Malt/Iga Ov5046$252,100
PanzygaImmun Glob G(Igg)-Ifas/Glycine27$224,864
EnspryngSatralizumab-Mwge13$214,900
VumerityDiroximel Fumarate26$213,042
GammakedImmune Globul G/Gly/Iga Avg 4614$181,137
AubagioTeriflunomide15$170,884
CopaxoneGlatiramer Acetate28$164,886
GilenyaFingolimod Hcl11$150,400
Avonex (4 Pack)Interferon Beta-1a13$108,003
Dalfampridine ErDalfampridine167$98,994
Avonex Pen (4 Pack)Interferon Beta-1a12$97,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera, Vumerity, Avonex (4 Pack)$55,600$842,55595 claims
Genentech USA, Inc.Enspryng$138$214,90013 claims
NovartisGilenya$409$150,40011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,623 neurology providers in New York.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →